P2Y12 receptor antagonists:: a rapidly expanding group of antiplatelet agents

被引：55

作者：

Cattaneo, M ^{[1
]}

机构：

[1] Univ Milan, Osped San Paolo, Unita Ematol & Trombosi, I-20142 Milan, Italy

来源：

EUROPEAN HEART JOURNAL | 2006年 / 27卷 / 09期

关键词：

D O I：

10.1093/eurheartj/ehi851

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1010 / 1012

页数：3

共 9 条

[1] Aspirin and clopidogrel - Efficacy, safety, and the issue of drug resistance [J].

Cattaneo, M .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2004, 24 (11) :1980-1987

[2]

CATTANEO M, 2006, IN PRESS PLATELETS

[3] Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis:: a double-blind comparison to clopidogrel with aspirin [J].

Husted, S ;

Emanuelsson, H ;

Heptinstall, S ;

Sandset, PM ;

Wickens, M ;

Peters, G .

EUROPEAN HEART JOURNAL, 2006, 27 (09) :1038-1047

[4] Pharmacology of CS-747 (Prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity [J].

Niitsu, Y ;

Jakubowski, JA ;

Sugidachi, A ;

Asai, F .

SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2005, 31 (02) :184-194

[5] Advantages of fast-acting ADP receptor blockade in ischemic heart disease [J].

Nurden, AT ;

Nurden, P .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (02) :158-159

[6] Expert consensus document on the use of antiplatelet agents -: The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology [J].

Patrono, C ;

Bachmann, F ;

Baigent, C ;

Bode, C ;

De Caterina, R ;

Charbonnier, B ;

Fitzgerald, D ;

Hirsh, J ;

Husted, S ;

Kvasnicka, J ;

Montalescot, G ;

Rodríguez, LAG ;

Verheugt, F ;

Vermylen, J ;

Wallentin, L .

EUROPEAN HEART JOURNAL, 2004, 25 (02) :166-181

[7]

Peters G, 2004, HAEMATOLOGICA, V89, P14

[8] Preclinical and clinical studies with selective reversible direct P2Y12 antagonists [J].

van Giezen, JJJ ;

Humphries, RG .

SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2005, 31 (02) :195-204

[9] Randomized comparison of Prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention -: Results of the joint utilization of medications to block platelets optimally (JUMBO)-TIMI 26 trial [J].

Wiviott, SD ;

Antman, EM ;

Winters, KJ ;

Weerakkody, G ;

Murphy, SA ;

Behounek, BD ;

Carney, RJ ;

Lazzam, C ;

McKay, RG ;

McCabe, CH ;

Braunwald, E .

CIRCULATION, 2005, 111 (25) :3366-3373

← 1 →